There's a new frontier in treating autoimmune diseases. Today's treatments tamp down the friendly fire but don't fix what's ...

New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...

A new international multicenter study published in the Journal of Cellular and Molecular Medicine provides important real-world evidence on the use of CD19-targeted chimeric antigen receptor (CAR) ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence ...

CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in modern medicine. Equipping T cells, a key cell type of the immune system, ...

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have ...

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led ...

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...